Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study.

ABSTRACT:

Background

The safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) during fasting in patients with chronic kidney disease (CKD) remains underexplored. This study investigates the risk of acute kidney injury (AKI) in patients with CKD who are fasting and taking SGLT2i, and also examines the long-term estimated glomerular filtration rate (eGFR) outcomes over 6 months after fasting.

Methods

In this prospective cohort study conducted at the Kidney and Urology Centre, Alexandria, Egypt, 236 Muslim patients with CKD were enrolled during Ramadan. Patients were stratified into two groups: SGLT2i users (n = 56) and non-users (n = 180). Weekly serum creatinine and eGFR were monitored during Ramadan, with monthly follow-up for 6 months post-fasting. AKI was defined as an incr

SUBMITTER: Elkeraie A 

PROVIDER: S-EPMC12711977 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature